Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP75: Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDAECCO'24 Stockholm
Year: 2024
Authors: Rubín De Célix, Cristina
DOP76: Individual and comprehensive symptom resolution after induction and maintenance therapy with risankizumab in patients with moderately to severely active Ulcerative Colitis: A post-hoc analysis of INSPIRE and COMMAND studiesECCO'24 Stockholm
Year: 2024
Authors: Tinoco da Silva Torres, Joana
DOP77: Mesenchymal stem cell therapy for refractory Crohn’s perianal fistulas: a case seriesECCO'24 Stockholm
Year: 2024
Authors: Pronk, Annelies
DOP78: Efficacy of ozanimod by patient response trajectory subgroups identified using group-based trajectory modelling: a post hoc analysis of the phase 3 True North studyECCO'24 Stockholm
Year: 2024
Authors: Schreiber, Stefan Wolfgang
DOP79: Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohortECCO'24 Stockholm
Year: 2024
Authors: Verstockt, Bram
DOP80: Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO RegistryECCO'24 Stockholm
Year: 2024
Authors: Chaparro, María
DOP81: Rosnilimab, a novel PD-1 agonist monoclonal antibody, reduces T cell proliferation, inflammatory cytokine secretion, and PD-1high expressing CD4 and CD8 T cells: Results from a Phase 1 healthy volunteer clinical trialECCO'24 Stockholm
Year: 2024
Authors: Sibley, Cailin
DOP83: Intestinal epithelium-specific deletion of the Aryl hydrocarbon Receptor (AhR) reduces intestinal Tight Junction permeability thereby hindering homeostatic antigen sampling and tolerogenic immune responses.ECCO'24 Stockholm
Year: 2024
Authors: Saha, Kushal
DOP84: Colonic CD4+ T cell senescence is implicated in the progression of experimental colitis in aged miceECCO'24 Stockholm
Year: 2024
Authors: Zhang, Yang
DOP85: An anti-fibrotic role for eosinophils in a DSS colitis RAG-/- and an in vitro co-culture modelECCO'24 Stockholm
Year: 2024
Authors: Jacobs, Inge
DOP86: FOod Additives on the Mucosal barrier study (FOAM): Effect of five emulsifiers on inflammation, intestinal permeability, and the microbiome: preliminary results.ECCO'24 Stockholm
Year: 2024
Authors: Wellens, Judith
DOP87: Characterization of pathologic fibroblast and macrophage cell populations in colonic Crohn’s Disease with spatial transcriptomics.ECCO'24 Stockholm
Year: 2024
Authors: Gudiño, Victoria
DOP88: Lipids drive myofibroblast activation and the epithelial-mesenchymal transition process in Crohn’s Disease.ECCO'24 Stockholm
Year: 2024
Authors: Rizzo, Giulia
DOP90: Amphiregulin promotes colitis-associated intestinal fibrosis through activation of PI3K/AKT signaling in Intestinal fibroblastsECCO'24 Stockholm
Year: 2024
Authors: Zhao, Xiaojing
OP01: PROFILE: a multi-centre, randomised, open-label, biomarker-stratified clinical trial of treatment strategies for patients with newly-diagnosed Crohn’s diseaseECCO'24 Stockholm
Year: 2024
Authors: Noor, Nurulamin
OP02: IL23R-CAR-Tregs: creating a therapeutic breakthrough for Crohn’s DiseaseECCO'24 Stockholm
Year: 2024
Authors: Gertner-Dardenne, Julie
OP03: Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trialECCO'24 Stockholm
Year: 2024
Authors: Sands, Bruce E
OP04: Endoscopic healing in paediatric IBD perpetuates a persistent signature characterized by pathogenic Th17 cells and tissue-associated molecular and microbial drivers of diseaseECCO'24 Stockholm
Year: 2024
Authors: Schwerd, Tobias
OP05: Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 studyECCO'24 Stockholm
Year: 2024
Authors: Ferrante, Marc
OP06: Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND StudyECCO'24 Stockholm
Year: 2024
Authors: Schreiber, Stefan Wolfgang